Inhibitors of SARS-3CLpro: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation Studies

SARS-CoV from the coronaviridae family has been identified as the etiological agent of Severe Acute Respiratory Syndrome (SARS), a highly contagious upper respiratory disease that reached epidemic status in 2002. SARS-3CL(pro), a cysteine protease indispensible to the viral life cycle, has been identified as one of the key therapeutic targets against SARS. A combined ligand and structure-based virtual screening was carried out against the Asinex Platinum collection. Multiple low micromolar inhibitors of the enzyme were identified through this search, one of which also showed activity against SARS-CoV in a whole cell CPE assay. Furthermore, multinanosecond explicit solvent simulations were carried out using the docking poses of the identified hits to study the overall stability of the binding site interactions as well as identify important changes in the interaction profile that were not apparent from the docking study. Cumulative analysis of the evaluated compounds and the simulation studies led to the identification of certain protein-ligand interaction patterns which would be useful in further structure based design efforts.

[1]  V. Luzhkov,et al.  Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2'O)-methyltransferase. , 2007, Bioorganic & medicinal chemistry.

[2]  Xu Shen,et al.  Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. , 2008, Chemical & pharmaceutical bulletin.

[3]  Jiahai Shi,et al.  Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme , 2004, Journal of Biological Chemistry.

[4]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[5]  Y. Liu,et al.  Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. , 2006, Current pharmaceutical design.

[6]  A. Yang,et al.  Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease , 2008, Bioorganic & Medicinal Chemistry.

[7]  Debbie C. Mulhearn,et al.  Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors , 2008, Bioorganic & Medicinal Chemistry Letters.

[8]  M. Hsu,et al.  Mechanism of the Maturation Process of SARS-CoV 3CL Protease , 2005, Journal of Biological Chemistry.

[9]  Amedeo Caflisch,et al.  Discovery of Plasmepsin Inhibitors by Fragment‐Based Docking and Consensus Scoring , 2009, ChemMedChem.

[10]  G. Maggiora,et al.  Hit-directed nearest-neighbor searching. , 2005, Journal of medicinal chemistry.

[11]  Chi‐Huey Wong,et al.  Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. , 2005, Journal of medicinal chemistry.

[12]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[13]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[14]  Hui-Min Wang,et al.  Pharmacophores and biological activities of severe acute respiratory syndrome viral protease inhibitors , 2007 .

[15]  Elizabeth J Phillips,et al.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Günther,et al.  Severe acute respiratory syndrome: identification of the etiological agent , 2003, Trends in Molecular Medicine.

[17]  E. Freire,et al.  Development of Broad‐Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CLpro , 2008, Chemical biology & drug design.

[18]  J. Ziebuhr,et al.  Virus-encoded proteinases and proteolytic processing in the Nidovirales. , 2000, The Journal of general virology.

[19]  P. Liang,et al.  Individual and common inhibitors of coronavirus and picornavirus main proteases , 2009, FEBS Letters.

[20]  J. Vederas,et al.  Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase , 2008, Bioorganic Chemistry.

[21]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[22]  Alexander D. MacKerell,et al.  Lead Validation and SAR Development via Chemical Similarity Searching; Application to Compounds Targeting the pY+3 Site of the SH2 Domain of p56lck , 2005, J. Chem. Inf. Model..

[23]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[24]  N. Meanwell,et al.  Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus. , 2007, Infectious disorders drug targets.

[25]  T. Tong,et al.  Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. , 2009, Infectious disorders drug targets.

[26]  Daniel R McMasters,et al.  Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening. , 2009, Bioorganic & medicinal chemistry letters.

[27]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Po-Huang Liang,et al.  Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. , 2006, Journal of medicinal chemistry.

[29]  Jürgen Bajorath,et al.  Selected Concepts and Investigations in Compound Classification, Molecular Descriptor Analysis, and Virtual Screening , 2001, J. Chem. Inf. Comput. Sci..

[30]  F. López-Labrador.  Hepatitis C Virus NS3/4A Protease Inhibitors. , 2008, Recent Patents on Anti-Infective Drug Discovery.

[31]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[32]  L. Pedersen,et al.  A computational modeling and molecular dynamics study of the Michaelis complex of human protein Z-dependent protease inhibitor (ZPI) and factor Xa (FXa) , 2009, Journal of molecular modeling.

[33]  B. Tekwani,et al.  Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. , 2008, Bioorganic & medicinal chemistry.

[34]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[35]  Ting Xu,et al.  Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.

[36]  Mitchell A. Avery,et al.  Targeting the BH3 Domain Mediated Protein-Protein Interaction of Bcl-xL through Virtual Screening , 2010, J. Chem. Inf. Model..

[37]  Xu Shen,et al.  Discovering Severe Acute Respiratory Syndrome Coronavirus 3CL Protease Inhibitors: Virtual Screening, Surface Plasmon Resonance, and Fluorescence Resonance Energy Transfer Assays , 2006, SLAS Discovery.

[38]  Hsuan-Liang Liu,et al.  Homology models of main proteinase from coronavirus associated with SARS , 2004, Chemical Physics Letters.

[39]  R. Hilgenfeld,et al.  A Structural View of the Inactivation of the SARS Coronavirus Main Proteinase by Benzotriazole Esters , 2008, Chemistry & Biology.

[40]  Mark E. Tuckerman,et al.  Reversible multiple time scale molecular dynamics , 1992 .

[41]  C. Craik,et al.  Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. , 2007, Biochemistry.

[42]  Malik Peiris,et al.  Aetiology: Koch's postulates fulfilled for SARS virus , 2003, Nature.

[43]  Petra Schneider,et al.  Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase , 2008, ChemMedChem.

[44]  A. Velázquez‐Campoy,et al.  Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. , 2004, Biochemistry.

[45]  D. Bhattacharyya,et al.  Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation. , 2010, Journal of molecular graphics & modelling.

[46]  Y. Guan,et al.  Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage , 2003, Journal of Molecular Biology.

[47]  Jörg Rademann,et al.  Sensitized Detection of Inhibitory Fragments and Iterative Development of Non‐Peptidic Protease Inhibitors by Dynamic Ligation Screening† , 2008, Angewandte Chemie.

[48]  Kaixian Chen,et al.  pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses , 2005, Journal of Molecular Biology.

[49]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[50]  J. Ziebuhr,et al.  Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase , 1997, Journal of virology.

[51]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[52]  Arun K. Ghosh,et al.  Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. , 2005, Journal of medicinal chemistry.

[53]  M. James,et al.  Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-peptide Epoxide , 2005, Journal of Molecular Biology.

[54]  J. Vederas,et al.  A Mechanistic View of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-like Peptidase , 2007, Journal of Molecular Biology.

[55]  Raymond C Stevens,et al.  Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[57]  Peter Willett,et al.  Similarity Searching in Databases of Chemical Structures , 2007 .

[58]  Gianni Chessari,et al.  Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.

[59]  Brown Rd,et al.  An Evaluation of Structural Descriptors and Clustering Methods for Use in Diversity Selection , 1998 .

[60]  Q. Wanga,et al.  Human rhinovirus 3C protease as a potential target for the development of antiviral agents. , 2007, Current protein & peptide science.

[61]  Mitchell A. Avery,et al.  Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits , 2008, Bioorganic & Medicinal Chemistry.

[62]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[63]  P. Darke,et al.  The Herpesvirus Proteases as Targets for Antiviral Chemotherapy , 2000, Antiviral chemistry & chemotherapy.

[64]  Yong-Jun Jiang,et al.  Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions. , 2010, Journal of molecular graphics & modelling.

[65]  V. Soriano,et al.  HIV protease inhibitors: recent clinical trials and recommendations on use , 2009, Expert opinion on pharmacotherapy.

[66]  Luhua Lai,et al.  Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase , 2004, Journal of Biological Chemistry.

[67]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[68]  B. T. Phillips,et al.  Identification and SAR for a selective, nonpeptidyl thrombin inhibitor. , 1998, Bioorganic & medicinal chemistry letters.

[69]  E. Novellino,et al.  2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. , 2005, Journal of medicinal chemistry.

[70]  J. Powers,et al.  Irreversible inhibitors of serine, cysteine, and threonine proteases. , 2002, Chemical reviews.

[71]  G. Schneider,et al.  Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. , 2007, Journal of medicinal chemistry.

[72]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[73]  A. Caflisch,et al.  Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. , 2005, Journal of medicinal chemistry.

[74]  J. Vederas,et al.  Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro , 2007, Bioorganic & Medicinal Chemistry.

[75]  Robert D Clark,et al.  Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. , 1996, Journal of medicinal chemistry.

[76]  G. Gao,et al.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[77]  R. Gillespie,et al.  Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. , 2006, Bioorganic & medicinal chemistry letters.

[78]  Eric D. Brown,et al.  High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.

[79]  A. Patick,et al.  Protease Inhibitors as Antiviral Agents , 1998, Clinical Microbiology Reviews.

[80]  R F Schinazi,et al.  Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. , 2001, Journal of the American Chemical Society.

[81]  H. Iwaasa,et al.  Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[82]  Hao Chen,et al.  Virtual Screening of Novel Noncovalent Inhibitors for SARS-CoV 3C-like Proteinase , 2005, J. Chem. Inf. Model..

[83]  Jérôme Hert,et al.  Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..

[84]  Arun K. Ghosh,et al.  Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors , 2007, Bioorganic & Medicinal Chemistry Letters.

[85]  Z. Rao,et al.  Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design , 2007, Journal of Virology.

[86]  M. Klein,et al.  Constant pressure molecular dynamics algorithms , 1994 .

[87]  Berith F. Jensen,et al.  In silico prediction of membrane permeability from calculated molecular parameters. , 2005, Journal of medicinal chemistry.

[88]  Christian Drosten,et al.  Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro , 2005, Journal of Virology.

[89]  H. Doerr,et al.  Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. , 2006, Journal of medicinal chemistry.

[90]  Venkataraman Thanabal,et al.  Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. , 2009, ACS chemical biology.

[91]  Yu-An Huang,et al.  Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. , 2006, Journal of medicinal chemistry.

[92]  A. Pessi,et al.  Inhibiting viral proteases: challenges and opportunities. , 2002, Biopolymers.

[93]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[94]  M. James,et al.  Crystal Structures Reveal an Induced-fit Binding of a Substrate-like Aza-peptide Epoxide to SARS Coronavirus Main Peptidase , 2006, Journal of Molecular Biology.

[95]  Li Du,et al.  Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase N Terminus Is Indispensable for Proteolytic Activity but Not for Enzyme Dimerization , 2005, Journal of Biological Chemistry.

[96]  Pascal Furet,et al.  Structure-based design and protein X-ray analysis of a protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[97]  Y. Liu,et al.  3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. , 2004, Biochemistry.

[98]  J. Vederas,et al.  Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. , 2004, Journal of medicinal chemistry.

[99]  H. Matter,et al.  Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. , 1997, Journal of medicinal chemistry.